Newsroom

Company news, product launches and press coverage from EClinCloud.

Article illustrationNews9 min readEssential Knowledge on Hemophilia Assessment ScalesWant more after our last post? Here is a wealth of practical insights on assessment scales.Archived article cover: EClinCloud eCOA system passes CFDI inspection, supporting marketing approval of Raynovent's COVID-19 treatment leritrelvir tabletsNews4 min readEClinCloud eCOA System Passes CFDI Inspection, Supporting Marketing Approval of Raynovent's COVID-19 Treatment Leritrelvir TabletsOn March 23, 2023, in accordance with the relevant provisions of the Drug Administration Law and under the special drug approval procedures, the National Medical Products Administration (NMPA) granted conditional marketing approval to leritrelvir tablets (brand name: Leruiling), a Category 1 innovative drug submitted by Guangdong Raynovent Biotech Co., Ltd. (hereinafter referred to as "Raynovent"). The drug is an oral small-molecule therapy for novel coronavirus infection, indicated for the treatment of adult patients with mild-to-moderate novel coronavirus infection (COVID-19).News header image for "Worried about being replaced by ChatGPT? Join EClinCloud and be irreplaceable!"News1 min readWorried about being replaced by ChatGPT? Join EClinCloud and be irreplaceable!Join EClinCloud's "Cloud Wings" program—united in purpose and soaring higher together!Article illustrationNews2 min read[Invitation] EClinCloud Invites You to the National Pharmaceutical Project Translation ForumDates: March 23–24, 2023 | Venue: Chengdu Yujiang HotelArticle illustrationNews4 min readWhat Momentum Follows Successive EMA and FDA Approvals of New Hemophilia Drugs? Take a Look!What you need to know about hemophilia gene therapy: 1, 2, 3...Article illustrationNews2 min readEClinCloud Invites You to the 2023 China (Ningbo) Biopharmaceutical Industry Development SummitDates: March 10–12, 2023 | Venue: Empark Grand Hotel Hangzhou Bay, NingboArticle illustrationNews4 min readThis dream company you missed went all out for its annual party!EClinCloud published "This dream company you missed went all out for its annual party!" on 2023-03-06. See the full article for text and photos.Article imageNews3 min readLive Webinar Preview | Applying eCOA to Achieve Patient-Centered Clinical ResearchFriday, March 3, 2023, 16:00–17:00. Join us online for the discussion.Article illustrationNews2 min readSomething a Little Different TodayOur goal: amaze the whole building with steaming, boiling, stir-frying, and pan-frying! Go, go, go!Article illustrationNews1 min readEClinCloud Wishes You a Happy Chinese New Year!As the seasons turn through eventful years, EClinCloud wishes you harmony and prosperity at home, peace, joy, and every blessing!Article illustrationNews6 min readLatest Updates on COVID-19 Drug Development and ApprovalsA detailed overview of the increasingly competitive COVID-19 drug development landscape.Archived article cover: Committed to serving global clinical research, Microsoft supports EClinCloud's accelerated global expansionNews6 min readCommitted to Serving Global Clinical Research: Microsoft Supports EClinCloud's Accelerated Global ExpansionIn 2015, drug review reform began, and innovation in China's pharmaceutical industry saw explosive growth. With steadily rising R&D investment, innovative drug pipelines expanded rapidly and the number of new drug launches continued to increase. Studies show that over the recent 10-year period (2010–2020), both Investigational New Drug (IND) applications and New Drug Applications (NDAs) in China achieved rapid growth. However, the key metric of "clinical trial phase duration" lengthened from 2572 days to 2688 days. This upward rather than downward trend has made improving clinical trial efficiency one of the most pressing pain points in new drug innovation today. Guided by a core mission centered on digital tools...